A Study of Olverembatinib in the Treatment of Ph+ ALL

NCT05466175 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia-Positive ALL

Interventions

DRUG: Olverembatinib
DRUG: Prednisone
DRUG: Vincristine

Sponsor

Chen Suning